Structure of BTK inhibitor Remibrutinib

BTK-selective covalent kinase inhibitor

Ph. I completed in HV, in Ph. II

SBDD from reversible BTK inhibitor and opt.

J. Med. Chem., Mar. 4, 2020

Novartis, Basel, CH

Remibrutinib (Novartis oral BTK-selective covalent kinase inhibitor clinical candidate)


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.